Watching Oncotelic Therapeutics, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planOncotelic Therapeutics, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Oncotelic continues to rely heavily on dilutive convertible note financing and share issuances to related parties (Mast Hill, Fourth Man, Pacific Pier) to fund operations, while remaining in default on approximately $5.0 million of Forever Prosperity Notes. Disclosure controls and internal controls over financial reporting remain ineffective due to persistent material weaknesses, and the company's going concern and liquidity risks appear unresolved from the prior filing.
Red Flags Detected (5)
Default on Forever Prosperity Notes (~$5.0 million principal and interest outstanding) as of June 30, 2026
Repeated dilutive stock issuances to note holders (Mast Hill, Fourth Man, Pacific Pier) totaling millions of shares over just seven months
Disclosure controls and procedures deemed not effective
2 more red flags detected
Key Takeaways
Company remains in default on a material note obligation (~$5.0 million) held by an affiliate of its JV partner Dragon, though no repayment has been demanded
Internal controls and disclosure controls remain ineffective, indicating unresolved governance and financial reporting risk
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.